In January 2013 a novel type of multicomponent protein-based vaccine against group B meningococcal disease was licensed by the European Medicines Agency. With the widespread use of the meningococcal serogroup C conjugate vaccines, serogroup B remains now the major cause of bacterial meningitis and septicaemia in young children in Europe. The aim of this study is to investigate the health and the economic outcomes of MenB vaccine introduction into the Italian routine mass vaccination programme.
Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme
MEREGAGLIA, MICHELA;MELEGARO, ALESSIA
2015
Abstract
In January 2013 a novel type of multicomponent protein-based vaccine against group B meningococcal disease was licensed by the European Medicines Agency. With the widespread use of the meningococcal serogroup C conjugate vaccines, serogroup B remains now the major cause of bacterial meningitis and septicaemia in young children in Europe. The aim of this study is to investigate the health and the economic outcomes of MenB vaccine introduction into the Italian routine mass vaccination programme.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Tirani MenB_PlosOne2015.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Pdf editoriale (Publisher's layout)
Licenza:
Creative commons
Dimensione
570.48 kB
Formato
Adobe PDF
|
570.48 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
